Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tredegar

9.03
+0.23462.67%
Volume:69.37K
Turnover:628.43K
Market Cap:308.53M
PE:-5.37
High:9.18
Open:8.75
Low:8.67
Close:8.80
Loading ...

TG Metals Ltd. Advances Van Uden Gold Project in Western Australia

TIPRANKS
·
06 May

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show

Benzinga
·
06 May

TG Therapeutics Shares Fall After 1Q Earnings Miss

Dow Jones
·
06 May

TG Therapeutics (TGTX) Lags Q1 Earnings Estimates

Zacks
·
05 May

TG Therapeutics' Q1 Swings to Net Income, Revenue Rises; Full-Year 2025 BRIUMVI Revenue Guidance Updated

MT Newswires Live
·
05 May

Earnings Flash (TGTX) TG Therapeutics Posts Q1 EPS $0.03, vs. FactSet Est of $0.17

MT Newswires Live
·
05 May

GUIDANCE: (TGTX) TG Therapeutics Expects 2025 Revenue About $575M, vs. FactSet Est of $552.9M

MT Newswires Live
·
05 May

TG Therapeutics Q1 EPS $0.03 Misses $0.17 Estimate, Sales $120.86M Beat $118.43M Estimate

Benzinga
·
05 May

TG Metals Resurveys Recent Historical Drilling at Western Australia Gold Project

MT Newswires Live
·
05 May

TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth

Zacks
·
30 Apr

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

GlobeNewswire
·
30 Apr

Tiangong International Completes Successful TG Tech Public Offering

TIPRANKS
·
30 Apr

Zydus Lifesciences Gets US FDA Final Nod for Niacin Extended-Release Tablets

MT Newswires Live
·
30 Apr

TG Therapeutics (NasdaqCM:TGTX) Sees Profitable Turn With Strong Quarterly Earnings

Simply Wall St.
·
29 Apr

Positive Revenue Outlook and Strategic Investments Reinforce Buy Rating for TG Therapeutics

TIPRANKS
·
23 Apr

Bank of America Securities Reaffirms Their Sell Rating on TG Therapeutics (TGTX)

TIPRANKS
·
17 Apr

TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why

Zacks
·
10 Apr

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

GlobeNewswire
·
10 Apr

Institutional shareholders may be less affected by Tredegar Corporation's (NYSE:TG) pullback last week after a year of 3.1% returns

Simply Wall St.
·
09 Apr

Buy Rating for TG Therapeutics Driven by Promising Briumvi Data and Strong Revenue Projections

TIPRANKS
·
08 Apr